Precision medicine in Alzheimer's disease aims to personalize treatment based on an individual's genetic, biomarker, and lifestyle data. This approach acknowledges the heterogeneity of Alzheimer's, where symptoms and progression vary widely among patients. By analyzing genetic markers like APOE ε4 allele and biomarkers such as amyloid and tau proteins, clinicians can better predict disease risk, tailor interventions, and monitor treatment responses more effectively. Precision medicine also explores targeted therapies that address specific molecular pathways implicated in Alzheimer's pathology, potentially slowing or modifying disease progression. Integrating advanced technologies like genomics and neuroimaging enhances early detection and intervention strategies, offering hope for more personalized and effective care for individuals affected by Alzheimer's and related dementias.
Jacqueline Tuppen
Cogs Club, United Kingdom
Yong Xiao Wang
Albany Medical College, United States
Kaoru Sakatani
The University of Tokyo, Japan
Suren A Tatulian
University of Central Florida, United States
Constantina Mizis
The Latino Alzheimer’s and Memory Disorders Alliance, United States
Paul Y Song
NKGen Biotech, United States
Marco Ruggiero
Silver Spring Sagl, Switzerland
Title : Cerebral vascular calcium signaling in diabetic alzheimer's disease-related dementias
Yong Xiao Wang, Albany Medical College, United States
Title : Deep learning-based risk assessment of cognitive impairment using health examination data
Kaoru Sakatani, The University of Tokyo, Japan
Title : Evaluation of the neuroprotective potential of indicaxanthin from opuntia ficus indica fruit against dysmetabolism-related neurodegeneration both in vivo and in vitro
Mario Allegra, University of Palermo, Italy
Title : Cogs Club: Making a difference
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Development of imaging based biomarkers for neurovascular abnormalities in neurodegenerative diseases
Jun Hua, Johns Hopkins University School of Medicine, United States
Title : Psychosocial considerations in management of corticobasal degeneration
Esraa Askar, Forest Hills Hospital, United States